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A method is provided for preparing benzoprostacyclins 
by the free-radical-catalyzed tandem alkene insertion 
into a 1,4-bisoxy-substituted cyclopent-2-ene intermedi-
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1 
FREE RADICAL-CATALYZED SYNTHESIS OF 
BENZOPROSTACYCLINS 
BACKGROUND OF THE INVENTION 
Prostacyclin (I, PGI2), first discovered in 1976, is one 
2 
(II) 
5 
of the most potent natural inhibitors of blood platelet 
aggregation. (See S. Moncado et al., Nature, 263, 663 10 
(1976) and R. Johnson et al., Prostaglandins, 12, 915 
(1976)). Unfortunately, its low metabolic stability due to 
enol ether hydrolysis greatly diminishes its pharmaco- wherein R 1 is a pharmaceutically acceptable cation, H 
or (Ct-C12)alkyl, preferably (Ct-C4)alkyl; R2 is H, 
(Ct-C12)-alkyl, (Ct-Cw)acyl or (C7-C13)aroyl; R8 isH 
or (Ct-CJ2)alkyl, and R9 is OR3 wherein R3 is H, 
(Ct-Ci2)alkyl, (Ct-Cw)acyl, or (C7-C13)aroyl; or R8 
and R9 taken together are keto; R4 isH, F, methyl or 
logical utility. Major interest of late has focused on the 15 
synthesis of more stable analogs, such as the benzopros-
tacyclins la-c, described by K. Ohno et al. in U.S. Pat. 
No. 4,301,164. 
•"('cooH 
o~, 
II , , 7 
I ,/ 
10 16 
HO OH 
~-Sr'" 
0 "'" ,,,,, ;~R 
HO ; 
OH 
!.' g_ 
Ia I n-CsH11 
Ib I CH(Me)CHzC=CCH3 
Ic 0 n-CsHu 
18 
17 19 
20 ethyl; R5 is (Ct-Cs)alkyl; A is -CH2-, -O-CH2-, 
-CH2-CH2- or -CH=CH-, and B is -(CH2. 
)n-Z- wherein n is 0-4 and Z is -CH2-CH2-, 
-CH=CH- or -C==C-. 
25 In compound II, the bonds at cyclopentane ring posi-
tions 8, 9, 11 and 12, individually are in either the alpha 
(extending below the plane of the cyclopentane ring, 
indicated by a broken line) or beta (extending above the 
30 plane of the cyclopentane ring, indicated by a wedged 
line) configuration, with the "natural" configuration 
shown for I. The natural or corresponding inverted 
configurations at Cts may be either (R) or (S). Prefera-
bly, the Cs and C9 cyclopentane ring bonds are both 
35 alpha (the "natural" configuration) or both beta. 
Two novel compounds which can be prepared in 
accord with the present method wherein Rl, A, R2, R3, 
R4, Band R5 are as described hereinabove, are depicted 
40 below (IIa, lib). 
(Ila) 
45 
50 
These compounds similarly exhibit substantial inhibi-
tion of platelet aggregation. 
Present synthetic approaches to the benzoprostacy-
clins are very lengthy and rather inefficient. For exam- 55 
ple, the synthesis of compound Ia as reported by H. 
Nagase et al., Tetrahedron Lett., 31,4493 (1990) requires 
steps. As reported by K. Ohno et al. in U.S. Pat. No. 
4,474,802, the synthesis of the Ct·methyl ester of lb 60 
requires at least 17 steps. 
Therefore, a need exists for efficient methods to syn-
thesize benzoprostacyclins. 
R4 
I ~CH-B-R5 
OR3 
(lib) 
SUMMARY OF THE INVENTION 
The present invention provides a method for the 
synthesis of benzoprostacyclins of general formula II. 
65 Representative compounds of formula II, wherein 
A=-CH2-CH2-, R2=R3=R4=H, B=-(CH2)3-
and R5=CH3, which were prepared in accord with the 
present method are listed in Table I, below. 
3 
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TABLE I 
BenzoErostac~clin Analogs 
Bond Orientation 
Compound No. Cs Cq 
II (Rl = Et) a a 
12(R1 = Et) a a 
13 (R1 = Et) a a 
15 (R 1 = Et) {3 {3 
12(R1 =H) a a 
Cu Ct2 
a /3 
a /3 
a {3 
{3 a 
a {3 
Cts=O 
a 
{3 
a 
{3 
amount of a free radical source, e.g., under essentially 
the same reaction conditions used to form Cwketo II. 
Preferably, R3 isH, and the C3-configuration is fixed, so 
that a C1s-S or C1s-R prostacyclin results. In either 
5 case, the C1-ester can then be saponified if necessary, to 
yield compounds of formula II wherein R 1 is H, and the 
C02H group can also be converted into a pharmaceuti-
cally-acceptable carboxylate salt. 
15(R1 =H) {3 {3 {3 a ----~--~~--~--~----~-----------a----- 10 
The present method employs intermediate III in the 
present synthetic method: 
(III) 15 
20 
wherein Rl is (Ct-Cl2) alkyl and A and R2 are as de- 25 
fined above. Preferably, the 1,4-cyclopentenyloxy 
bonds are both alpha, R2 isH, and R' is (Ct-C4)alkyl. 
As used herein, the term "alkyl" includes branched or 
straight-chain alkyl groups, or (C3-Cn)cycloalkyl, 
preferably (C3-C6)cycloalkyl. Aroyl is preferably 30 
(C7-C11)aroyl, e.g., benzoyl or naphthoyl, wherein the 
aryl ring is either unsubstituted or is substituted with 
1-4 (C1-C4)alkyl or 1-4 (C1-C4)alkoxy groups. The 
preferred acyl is acetyl. Preferably A and B are methy-
lene (-CH2-) or ethylene (-CH2-CH2-). Pre- 35 
ferred pharmaceutically-acceptable cations are alkali 
metal salts, NH4 +, or the carboxylic acid addition salts 
of non-toxic amines. 
In accord with the present method, a compound of 
the formula III, wherein R2 is as defined above, and 40 
preferably isH; R' is as defined above, and preferably is 
(C,-C12)alkyl and A is as defined above, and preferably 
is -CH2- or -CH2-CH2-, is reacted with a com-
pound of the formula IV: 
R7-CH=CH-C(O)-CH(R4)-B-Rs IV 45 
wherein R7 is tris(C1-C4)alkylSn or (phenyl)3Sn; R4, B 
and R5 are as described hereinabove; in the presence of 
a catalytic amount of a free radical source to directly 
yield the corresponding compound of formula II 50 
wherein RS and R9 taken together are keto. Preferably, 
the reaction is carried out in the presence of an organic 
solvent, and the free radical addition is thermally initi-
ated, e.g., at about so·-lso· c. 
The C1s-keto group of compound II can then be 55 
reduced to the corresponding C1s-hydroxy group by 
methods known to the art to yield compounds of for-
mula II wherein R 8 is H or (C1-C!2)alkyl and R9 is OH. 
Optionally, the moiety -CH=CH-C(O)-CH(R-
4)-B-RS in compound IV can be replaced by the 60 
moiety -CH=CH-CH(OR3)-CH(R4)-B-R5 by 
reaction of the intermediate III with a compound of 
formula V: 
. v 65 
wherein R8is H or (C!-C12)alkyl and R3, R4, RS, R7 and 
B are as described above, in the presence of a catalytic 
The moiety -CH=CH- may be cis or trans. It is 
preferably trans in compound IV, and cis in moieties A 
and B in compounds II or III. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The preparation of a preferred embodiment of inter-
mediate III is summarized in Scheme 1. 
OR 
I~ 
u~ 
l(R=H) a 
2 (R =allyl) 
Scheme I 
Steps (a)-(g) are summarized in Table II below, 
wherein the numbers preceding the reactants are mole 
ratios: l mole of l-8, unless otherwise noted. 
5 
TABLE II 
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6 
diastereomers 12 (R=Et) and 13 (R=Et) in a ratio of 
about 1:5, in accord with Scheme 3, below. 
Scheme 3 
~ -Sco,R ~ -SC~R 
>~+~ II (5)-B!NAL-H -100' c. ~-78' c. 56o/c 
~ 00 ~ 00 
S~nthesis of Comi!ound 9 
Step Reactants 
a 1.2 allyl bromide, 
1.2 K2C03, acetone 
b 0.8 MeAJCJ2, -20' C. 
c t-butyldimethylsilyl 
chloride. imidazole 
d ozone, - 78' C./Me2S 
e Ph3P=CHC02Et 
f H2. cat. Pt02 
g n-Bu4NF 
h 1.5-cyclopentadiene 
monoepoxide, 2o/c Pd(PPh3)4, 
THF 
12 (R = Et) 
Yield 
94o/c 
70% 
90o/c 
83% 
83% 
90% 
94o/c 
72o/c 
!3 (R = Et) 
1:5 
20 
A more direct approach to the desired 15-(S) isomer 
used the chiral ')'-Stannyl allylic alcohol 14, although 
few such unactivated vinylic stannanes appear to have 
previously been used as a radical trap. See, for example, 25 G. A. Russell et al., J. Arner. Chern. Soc., 106, 4622 
(1984) and G. A. Russell eta!., Organorneta!lics, 7, 696 
(1988). Compound 14 was prepared as described by M. 
Suzuki et al., Tetrahedron, 46, 4809 (1990). 
30 
Scheme 4 
racemic 9 + 
0.1 AIBN 
The requisite regia- and stereochemistry is efficiently 
introduced by the palladium-catalyzed opening of a 
vinylic epoxide. See, D. R. Deardorff et a!., Tetrahedron 
Lett., 26, 5615 (1984). 35 
4n-BuJSn~ !3~~~~~n~6 h ;:,. 
41% OH 
14 
COzR 
The reaction of 9 with trans-1-(tri-n-butylstannyl)-
oct-1-en-3-one (10) and azobisisobutyronitrile (AIBN), 
in a mole ratio to 9 of 4:0.1, respectively, proceeded in 
80o/c yield at 90° C. in toluene to give compound 11, as 
shown in Scheme 2, below. 40 
Scheme 2 
0.1 AIBN 
. toluene ;:,. 9 + 10 (4 equtv) 90• C., 12 h 
80o/c 
11 
Mechanistically, this process is believed to involve 
formation of a aryl radical of 9 that in turn self-adds to 
produce a free radical at nascent position 12. This active 
species reacts in situ across the C-Sn bond of 10 to 
yield 11. 
(S)-BINAL-H reduction of enone 11 in accord with 
the procedure of R. Noyori et al., J. Arner. Chern. Soc., 
106, 6717 (1984), was unselective, affording a mixture of 
45 
50 
60 
0 
12 (R = Et) + 
OH HO 
15 (R = Et) 
1:1 
A 1:1 mixture of diastereomers cleanly separable by 
flash chromatography was obtained in 41% overall 
yield. Separation and hydrolysis afforded the corre-
spon(}ing chiral benzoprostacyclins 12 (R=H) and 15 
(R=H) in 72% and 74% yields respectively. 
In carrying out the synthesis of the compound of 
formula II, the aryl iodide III is preferably combined 
with an excess of compound IV, e.g., preferable in a 
mole ratio of III:IV of about 1:1.25-20, in a suitable 
organic solvent which is relatively inert to free radical 
species, i.e., in benzene, toluene, xylene and the like. 
The reaction mixture is preferably stirred at about 
65 50°-150° C. for about 5-48 hr. under an inert atmo-
sphere, with an effective catalytic amount of a source of 
free radicals, or "free radical initiator." Useful free 
radical initiators include AIBN, azobiscyclohexylni-
5,169,959 
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trile, benzoyl peroxide, other aroyl peroxides and the 
like. For other useful free radical sources, see U.S. Pat. 
No. 4,590,014, the disclosure of which is incorporated 
herein by reference, and C. C. Walling, Tetrahedron 
Syrnp., 41, 3887 (1985). The crude product is extracted, 5 
i.e., into ethyl acetate and can be purified by chroma-
tography. 
Compounds of formula V, wherein R7 is a trialkyl-
stannyl group, R8is Hand R9 is OR3 can be prepared as 
disclosed by 1. K. Stille, in Angew. Chern. Int. Ed. 10 
Engl., 25, 508 (1986), M. Ochiai et al., Tet. Letters, 24, 
4025 (1983), and by G. Keck et al., J. Org. Chern .. 52, 
2958 (1987). For example tri-n-butyltin hydride can be 
reacted with a protected 3-hydroxy-1-alkyne as dis-
closed in U.S. Pat. No. 4,230,879. Compounds of for- 15 
mula IV, wherein R7 is a trialkylstannyl group, and R8 
and R9taken together are keto, e.g., 10, can be prepared 
as disclosed by W. Hartmann eta!., Angew. Chern. Int. 
Ed. Engl., 21, 751 (1982); R. F. Newton et al., Synthesis, 
449 (1984) and W. Skuballa, J. Med. Chern., 29, 313 20 
(1986). 
The reduction of Cts-keto-benzoprostacyclins to 
yield compounds of formula II, wherein R3=H can be 
accomplished with borohydride reducing agents such 
as zinc borohydride or sodium borohydride, or with 25 
chiral reducing agents such as lithium aluminum hy-
dride/a,a-binaphthol ((S)-BINAL-H), as described in 
detail in the working Examples, below and in Aldri-
chirnica Acta, 16, 14 (1983). The free Cu11-0H or Cts-
OH groups can then be acylated or aroylated by con- 30 
ventional methodologies, e.g., via reaction with anhy-
drides or acid chlorides in the presence of an organic 
base. Compounds of formula II wherein R 1 is alkyl can 
be converted into the -corresponding carboxylic acids 
by saponification with alkali metal hydroxides in alco- 35 
holic solvents followed by neutralization of the reaction 
mixture. Pharmaceutically-acceptable cations (RI) in-
clude alkali metal salts and the amine salts disclosed in 
K. Ohno. et al. (U.S. Pat. No. 4,474,802), which is incor-
porated by reference herein. 40 
The reaction methodology employed to prepare 
compound 9, as outlined in Scheme I, can be readily 
modified to prepare other aryl iodides of general for-
mula III, e.g., by the use of aldehydes of varying chain 
length in step (e). Compound III wherein A is CH=CH 45 
and R2 is H is readily prepared by deprotecting com-
pound 6, e.g., via step (g). 
sured. The compounds listed above are injected into the 
vein through an indwelling catheter. These compounds 
exhibit substantially the same activity as prostaglandin 
Et at the same dose of 0.05 to 100 ~J-g/kg and have a 
longer duration of action than prostaglandin Et. 
An anti-thrombotic agent containing any of these 
benzoprostacyclins as the active component may be 
applied to prevent clotting in extracorporeal circula-
tion, treatment of a disturbance of peripheral circulation 
such as Buerger's disease and Raynaud's disease, pre-
vention and treatment of myocardial infarction, angina 
pectoris and cerebral infarction, prevention of TIA, 
treatment of diabetic thrombosis and prevention and 
treatment of arteriosclerosis. 
For the treatment of Buerger's disease, the pharmaco-
logically effective intravenous dose of a compound of 
the invention is 0.001 to 100 ~J-g/kg/min. In case of 
using the compound as an anti-thrombotic agent, 0.001 
to 50 mg of the compound is orally administered to a 
patient one to three times a day, and in case of using the 
compound as a blood pressure-reducing agent, 0.01 to 
50 mg of the compound is orally administered to a pa-
tient one to three times a day. 
The benzoprostacyclins can be orally administered as 
a form of a solid substance containing excipients such as 
starch, lactose, and sucrose, or can be parenterally ad-
ministered in a form of a sterilized aqueous solution. 
Such a solution may contain another solute, for in-
stance, glucose or sodium chloride in an amount suffi-
cient to make the solution isotonic. Various prepara-
tions for oral administration, injections, infusions, eye 
drops and suppositories can be prepared. 
The invention will be further described by reference 
to the following detaile9, examples. 
EXAMPLE 1 
Preparation of Compound 2 
A solution of o-iodophenol (6.6 g, 30 mmol), allyl 
bromide (4.0 g, 33 mmol) and potassium carbonate (4.6 
g, 3.3 mmol) in 7.5 ml of acetone was refluxed for 8 hr. 
The reaction mixture was diluted with 40 ml of water, 
and extracted with ether (2 X 25 ml). The organic phase 
was washed with brine (25 ml), and then dried over 
MgS04. Concentration, followed by flash chromatog-
raphy, gave compound 2 as a colorless oil: 6.8 g, 94% 
yield, IH NMR (CDCl3) B 7.77 (dd, 1=17.4 and 10.5 
and 7.8 Hz, 1.5 Hz, 1 H, Ar), 7.27 (dt, 1 = 1.8 and 7.8 Hz, 
Bioassays 1 H, Ar), 6.80 (dd, 1 = 7.8 and 1.2 Hz, 1 H, Ar), 6. 70 (dt, 
The compounds prepared by the present method 50 1=7.8 and 1.2 Hz, 1 H, Ar), 6.06 (ddt, 1=17.4 and 10.5 
exhibit potent platelet aggregation inhibiting activity and 7·8 Hz, 1 H, HC=C), 5.52 (dd, 1 = 17.4 and 1.8 Hz, 
d blood d · · · b d'l t' 1 H, HC=C), 5.31 (dd, 1 = 10.5 and 1.2 Hz, 1 H, an pressure ecreasmg act!v1~y. y vaso 1 a 10n. HC=C), 4.59 (dt, 1 = 4.8 and 1.5 Hz, 2 H, cH2); 13C Th~ e~cacy ~fthe comP<;>und to mh1b1t platelet aggre- NMR (CDC!) 8 157.09 139.51 132.57 129 35 122 66 gat10n IS exammed accordmg to Born's method (Nature, 3 ' ' ' · ' · 1 ' 194, 927 (1962)). The blood is collected from humans or 55 117·59, 112.58, 86.72, 69.68; IR (neat) 582, 1477 em- · 
anesthetized rabbits. The blood is anti-coagulated with EXAMPLE 2 
a 3.8% aqueous solution of sodium citrate in an amount 
of a tenth volume of the blood and centrifuged for 10 
minutes at 200Xg to obtain platelet rich· plasma. After 
pretreatment of the platelet rich plasma with the benzo- 60 
prostacyclin, aggregation is measured by aggregometer 
with arachidonic acid, adenosine-2-phosphate(ADP) or 
collagen as the aggregation inducer. It is shown that 
compounds 11 (R=Et), 12 (R=H or Et), 13 (R=Et), 
and 15 (R=H or Et) exhibit potent inhibitory activity. 65 
To examine the efficacy of a benzoprostacyclin to 
reduce blood pressure, the blood pressure of the carotid 
artery of rats under pentobarbital anesthesia is mea-
Preparation of 6-allyl-2-iodophenol 3 
To a solution of compound 2 (7.0 g, 27 mmol) in 130 
ml of hexane was added MeAICh (Aldrich, 1.0 M in 
hexane, 22 ml 22 mmol) dropwise at - 20• C. After the 
reaction mixture was stirred for 2 hr. at -20• C. under 
nitrogen, the reaction was quenched by adding water 
(40 ml) and the mixture slowly warmed to room tem-
perature with swirling. Ethyl acetate (30 ml) was added 
to the reaction mixture, then stirring was continued for 
5 min. After separating phases, the organic phase was 
washed with water (30 ml) and brine (30 ml), then dried 
9 
5,169,959 
and concentrated. The residue was purified by flash 
chromatography with 15:1 hexane/EtOAc to give 
product 3: 4.9 g, 70% yield; Rp0.38 (20:1 hex-
ane/EtOAc); lH NMR (CDC~)) a 7.51 (dd, 1= 1.2 and 
10 
HC=C), 4.18 (q, 1=7.2 Hz, 2 H, OCHz), 3.53 (dd, 
1=6.9 and 1.5 Hz, 2 H, CHz), 1.27 (t, 1=7.2 Hz, 3 H, 
CH3), 1.05 (s, 9 H, t-BuSi), 0.32 (s, 6 H, Me2Si); l3C 
NMR (CDCl3) a 166.32, 153.31, 146.18, 138.75, 130.60, 
5 129.52, 123.61, 122.93, 91.09, 60.36, 33.94, 26.42, 18.94, 
14.32, -1.49. 
7.8 Hz, 1 H, Ar), 7.07 (d, 1=7.8 Hz, 1 H, Ar), 6.62 (t, 
1=7.8 Hz, 1 H, Ar), 5.98 (ddt, 1=17.4 and 9.6 and 6.6 
Hz, 1 H, HC=C), 5.37 (s, I H, OH), 5.12 (m, 1 H, 
HC=C), 5.07 (m, 1 H, HC=C), 3.43 (d, 1 = 6.6 Hz, 2 H, 
CH2); Be NMR (CDCl3) a 152.60, 136.33, 136.Dl, 
130.73, 126.81, 122.42, 6.22, 86.41, 35.56; IR (neat) 3487 10 
(OH), 1593, 1234 cm-l; LRMS m/z (relative intensity) 
51.1 (34), 77.1 (47), 105.1 (58), 118.1 (41), 133.1 (42), 
260.0 (M +, 100). 
EXAMPLE 6 
Preparation of Compound 7 
To a three neck flask equipped with a hydrogen-filled 
gas balloon were added a,/3-unsaturated ester 6 (619 
mg, 1.36 mmol), ethanol (20 ml), 2 N aqueous HCl (0.4 
ml) and PtOz (Aldrich, 60 mg). The reaction was 
EXAMPLE 3 
Preparation of Compound 4 
15 flushed with hydrogen gas using an aspirator, and then 
stirred for 1 hr. at room temperature under the hydro-
gen balloon pressure. After the reaction was neutralized 
with 3 N aqueous NaOH (0.27 ml), it was poured into 
100 ml of ethyl acetate (EtOAc). The solution was 
To a solution of compound 3 (4.9 g, 18.7 mmol) and 
imidazole (3.2 g, 47.1 mmol) in 20 ml of DMF was 
added t-butyldimethylsilyl chloride (3.1 g, 20.5 mmol) 
dissolved in 15 mmol of DMF at room temperature 20 
under nitrogen. After mixture was stirred for 12 hr. at 
room temperature, it was extracted with hexane (50 
ml X 8). The hexane phase was concentrated and then 
flash chromatographed to give compound 4: 6.3 g, 90% 
yield; Rp0.52 (hexane); IH NMR (dd, 1 = 7.8 and 1.8 25 
Hz, 1 H, Ar), 7.11 (dd 1 = 7.8 and 1.8 HZ, 1 H, Ar), 6.66 
(t, 1 = 7.8 Hz, 1 H, Ar), 5.86 (ddt, J = 17.4 and 9.6 and 6.6 
Hz, 1 H, C=CHCH2), 5.08 (m, 2 H, H2C=C), 3.39 (d, 
1 = 6.9 Hz, 2 H,CH2), 1.06 (s, 9 H, t-BuSi), 0.331 (s, 6 H, 
SiMez). 30 
EXAMPLE4 
washed with brine (50 ml, 25 ml) and concentrated in 
vacuo. The residue was purified by flash chromatogra-
phy to give compound 7: 562 mg, 90% yield; Rp0.52 
(7:1 hexane/EtOAc); lH NMR (CDCl3) a 7.62 (dd, 
1 =7.8 and 1.5 Hz, 1 H, Ar), 7.10 (dd, 1 =7.8 and 1.5 Hz, 
1 H, Ar), 6.64 (t, 1 =7.8 Hz, 1 H, Ar), 4.11 (q, 1 =7.2 Hz, 
2 H, OCHz), 2.66 (t, 1=7.8 Hz, 2 H, CHz), 2.27 (t, 
1 =7.5 Hz, 2 H, CHz), 1.88 (m, 2 H, CH2), 1.25 (t, 1 =7.2 
Hz, 3 H, CH2), 1.04 (s, 9 H, t-BuSi), 0.32 (s, 6 H, SiMe2). 
EXAMPLE 7 
Preparation of Compound 8 
To a solution of compound 7 (2.85 g, 6.2 mmol) in 60 
Preparation of Compound 5 ml of THF at -78° C. was added n-B114NF (Aldrich, 
Ozone was passed through a solution of compound 4 35 1.0 M in THF, 6.2 ml, 6.2 mmol). The reaction mixture (722 mg, 1.9 mmol) in 19 ml of methanol at _ 78° c. was stirred for 1 hr. at -78° C., then allowed to warm 
until the deep blue color persisted (about 15 min.). The to oo C., and quenched by adding water (10 ml). The 
reaction was flushed with nitrogen gas and 8 ml of mixture was poured into 50 ml of ethyl acetate, and 
CH3SCH3 was added at -78° C. The reaction mixture washed with water (25 ml) and brine (20 ml). The or-
was then allowed to stir for 30 min. at -78° C., for 1 hr. 40 ganic p~ase was dried and concentrated. !he residue 
at oo C. and for another 30 min. at room temperature. was punfied by flash chromatography With 4:1 hex-
The methanol solvent was evaporated under reduced ane/EtOAc to give compound 8: 2.02 g, 94% yield; 
pressure, and 60 ml of ether was then added to the R:=0.37 (5:1 hexane/EtOAc); 1H NMR (CDCh) a 7.53 
residue. After the mixture was washed with water (10 (dd, 1 =7.8 and 1.2 Hz, 1 H, Ar), 7.05 (dd, 1 =7.8 and 1.2 
ml) and brine (20 mlX2), it was dried and concentrated. 45 Hz, 1 H, Ar), 6.58 (t, 1 =7.8 Hz, 1 H, Ar), 6.18 (s, 1 H, Flash chromatography gave product 5: 638 mg, 83% OH), 4.15 (q, 1=7.2 Hz, 2 H, CHz), 2.69 (t, 1=7.2 Hz, 
yield; Rp0.63 (3:1 hexane/EtOAc); lH NMR (CDC13) 2 H, CH2), 2.36 (t, 1=7.2 Hz, 2 H, CH2), 1.91 (m, 2 H, 
8 6 9.63 (t, 1 = 2.1 Hz, 1 H, CHO), 7. 74 (dd, J = 8.1 and CH2), 1.27 (t, J = 7.2 Hz, 3 H, CH2); l3C NMR (CDCl2) 
1.5 Hz, 1 H, Ar), 7.09 (dd, 1 =7.5 and 1.5 Hz, 1 H, Ar), a 174.15, 152.96, 136.44, 130.64, 128.05, 122.06, 86.28, 
6.72 (t, 1=7.5 Hz, 1 H, Ar), 3.68 (d, 1=2.1 Hz, 2 H, 50 60.59, 33.28, 30.54, 24.68, 14.24; IR (neat) 3373 (OH), CH2), 1.05 (s, 9 H, t-BuSi), 0.32 (s, 6 H, SiMe2); l3C 2980, 2957, 1707 (C=O), 1445 cm-1. HRMS m/z cal-
NMR (CDC}J) 8 199.34, 153.92, 139.70, 131.54, 124.26, culated for C12H!sOJI 334.00660, found 334.00617. 
123.81, 91.23, 46.16, 26.37, 18.85, -1.52. EXAMPLE 8 
55 Preparation of Compound 9 
Preparation of Compound 6 To a dried flask was added Pd(PPh3)4 (18 mg, 0.016 
EXAMPLE 5 
To a solution of (carboxymethylene)triphenylphos- mmol). To this was added compound 8 (264 mg, 0.79 
phorane (Aldrich, 3.88 g, 11.5 mmol) dissolved in 30 ml mmol) in 2 ml of THF, and the reaction mixture was 
of CH2Clz was added dropwise at room temperature stirred in an ice-water bath. Cyclopentadiene mono-
aldehyde 5 (3.57 g, 9.3 mmol) dissolved in 14 ml of 60 epoxide (97 mg, 1.18 mmol) in 2 ml ofTHF was added 
CH2Clz. After the reaction was stirred for 12 hr. at dropwise at oo C., and stirring was continued for 20 min. 
room temperature, it was concentrated in vacuo and at this temperature and another 24 hr. at room tempera-
purified by flash chromatography with 5:1 hex- ture. The reaction mixture was concentrated. The resi-
ane/EtOAc to give ester 6: 3.52 g, 83% yield; Rp0.46 due was purified by flash chromatography with 2:1 
(5:1 hexane/EtOAc); lH NMR (CDCl3) a7.67 "(dd, 65 hexane/EtOAc to give product 9: 235 mg, 1% yield; 
1 =7.8 and 1.5 Hz, 1 H, Ar), 7.05 (dd, 1 =7.5 and 1.5 Hz, R2=0.21 (2:1 hexane EtOAc); IH NMR (CDC]J) a 7.58 
1 H, Ar), 6.99 (dt, 1=15.6 and 6.6 Hz, 1 H, HC=C), (dd,1=7.8and 1.5Hz, 1 H,Ar), 7.15(dd,1=7.8and 1.5 
6.66 (t, 1 = 7.5 Hz, 1 H, Ar), 5.80 (d, 1 = 15.6 Hz, 1 H, Hz, 1 H, Ar), 6. 77 (t, J = 7.8 Hz, 1 H, Ar), 6.09 (m, 1 H, 
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HC=C), 6.01 (m, 1 H, HC=C), 5.11 (m, I H, CHOAr), (m, 1 H), 2.66-2.51 (m, 2 H), 2.38 (d, J=l5.0 Hz, 1 H, 
4.68 (m, 1 H, CHOH), 4.12 (q, J =7.2 Hz, 2 H, OCH2), CH2 in cyclopentane), 2.27 (dt, J = 1.5 and 7.2 Hz, 2 H), 
2.85 (m, 2 H), 2.60 (ddd, J = 15.3 and 9.6 and 6.0 Hz, 1 2.15 (dt, J = 15.0 and 5.4 Hz, 1 H, CH2 in cyclopentane), 
H, CH2 in cyclopentane), 2.30 (dt, J = 1.8 and 6.9 Hz, 2 pentane), 2.04-1 81 (m, 2 H), 1.63 (m, 4 H), 1.34 (m, 6 
H), 2).06 (dt, J = 14.7 and 3.9 Hz, 1 H, CH2 in cyclopen- 5 H), 1.25 (t, J =7.2 Hz, 3 H, CH2), 0.92 (t, J =6.0 Hz, 3 H, 
tane , 1.88 (m, 2 H), 1.25 (t, J =6.3 Hz, 3 H, CH2), 0.88 CH3); IR (neat) 3396 (OH), 2930, 1734 (C=O), 1458 (m, 1 H, OH); 13C NMR (CDCh) a 173.69, 156.22, em-; HRMS m/z calculated for C2sH360s416.25627 
138.09, 137.98, 136.65, 133.55, 130.56, 125.87, 92.45, found 416.25574. 
85.71, 74.97, 60.52, 41.28, 33.50, 30.86, 25.47, 14.28· IR C d 13 (R ) R (neat) 3350 (OH, 2959, 1720 (C=O), 1599, 1462, i352 10 ompoun. 1 =Et : ,=0.38 (1:2 hex-
em-!; HRMS m/z calculated for C!7H2!041 416.04847, ane/EtOAc), H NMR (CDCb) a 6.96 (d, J=7.5 Hz, 1 
found 416.04747. H, AR), 6.91 (d, J=7.5 Hz, 1 H, Ar), 6.73 (t, J=7.5 Hz, 
1 H, Ar), 5.69 (m, 2 H, HC=CH), 5.32 (t, J=7.5 Hz, 1 
H, CHOAr), 4.14 (m, 1 H, CHOH), 4.07 (m, 3 H), 3.88 
(t, J=9.3 Hz, 1 H), 2.74 (m, IH), 2.57 (m, 2 H), 2.35 (d, 
EXAMPLE9 
15 J = 15.0 Hz, 1 H, CH2 in cyclopentane), 2.27 (m, 2 H), 
To a solution of compound 9 (70 mg, 0.17 mmol) in 2.14 (dt, J = 15.0 and 5.7 Hz, 1 H, cH2in cyclopentane), 
Preparation of Compound 11 
1.7 ml of toluene were added compound 10 (279 mg, 1 99 ( 1 H) 1 91 1 81 ( 3 H) 1 0 67 I) · · m, , · - . m, , .49 (m, 2 H), 1.28 (m, 
. mmo , prepared as disclosed by M. E. Jung et ~!., 6 H), 1.24 (t, J =7.5 Hz, 3 H, CH:), 0.88 (t, J =6.6 Hz, 3 
Tetrahedron Lett., 23, 3851 (1982), and AlB~ (A~dnch H, CHJ); IR (neat) 3443 (OH), 2987, 1732 (C=O), 1593, 
Chern. Co., ~.8 mg, 0.~17 mmol). The resultm~ muture 20 1456 cm-1; HRMS m/z calculated for c 25H36o 5 w~s placed mto an ml ba!h preheated to 90 C. and 416.25627, found 41 6.25591. 
stmed for 12 hr. After coohng to room temperature, the (2) p d B ( · d' · f mixture was purified by flash chromatography with 1:1 d ;)oce ure VIa Irect conversion rom com-
hexane/EtOAc to give product 11 as a yellow oil: 65 poun . . 
mg, 80% yield; R2=0.32 (1:1 hexane/EtOAc); 'H 25 In a VIal wer~ placed :acemic compoun? 9 (100 mg, NMR (CDClz) a 6.93 (d, J =7.S Hz, 1 H, Ar), 6.86 (d, 0.24 mmol), optically active y-sta~nyl ally he alcohol14 
J = 7.5 Hz, 1 H, Ar), 6.84 (dd, J = 16.2 and 9.6 Hz, 1 H, (401 mg, 0.96 mmol) prepared as disclosed by M. Suzuki 
HC=C), 6.73 (t, J=7.5 Hz, 1 H, Ar), 6.19 (d, J=l6.2 eta!., Tetrahedron, 46,4809(1990),toluene(2.4ml)and 
Hz, 1 H, C=CH), 5.38 (dd, J=7.5 and 6.3 Hz, 1 H, A!BN (Aldrich, 3.9 mg, ?.024 mmol). The reaction 
CHOAr), 4.28 (m, 1 H, CHOH), 4.09 (m, 2 H, ocH2), 30 m~xture was heated for 130 C. for 16 hr. The resulting 
3.98 (t, J = 8. 7 Hz, 1 H), 2~86 (dt, J = 3.9 and 9.6 Hz, 1 m1xture was cooled to room temperature, and purified 
H), 2.66-2.43 (m, 4 H) 2.25 (m, 2 H), 2.17 (ddd, J = 15.3 by flash chromatography using 1:1 to 1:2 hex-
and 6.4 and 4.1 Hz, I H), 2.09 (d, J =5.7 Hz, 1 H), 2.02 ane/Et.OAc to give optically active 12 (R=Et) (22 mg, 
(m, I H), 1.86 (m, 1 H), 1.59 (m, 3 H), 1.41-1.22 (m, 71f), 21% y1eld) and 15 (R=Et) (19 mg, 20% yield). The 
0.88 (t, J =6.9 Hz, 3 H, CHz); IR (neat) 3466 (OH), 2930, 35 spectral data for this compound are the same as for the 
1666 (C=O), 1372, 1456 cm-1; HRMS m/z calculated racemic mixture 13 (R=Et). 
for C2sH340s 414.24062, found 414.24080. 
EXAMPLE 10 
Preparation of ( + )-5,6,7-trinor-4,8-inter-m-phenylene 
PGiz [12 (R=H)] 
Preparation of compounds 12 (R=Et) and 13 (R=Et) 40 To a solution of compound 12 (R=Et) (40 mg, 0.10 
(I) Procedure A (via reduction of compound 11) mmol) in 1.2 ml of THF was added 0.6 ml of 3 N aque-
To a solution of LiAlH4 (Aldrich, 0.9l ml, l.O Min ous NaOH. After the reaction mixture was stirred for 4 THF, 0.91 mmol) was added ethanol (0.46 ml, 2.0 Min days at room temperature, it was neutralized with 2 N 
THF, 0.91 mmol) dropwise at room temperature. To aqueous HCI. The organic phase was decanted with 
this was added (S)-binaphthol (Aldrich, 258 mg, 0.91 45 ethyl acetate (3 X 5 ml), then dried over MgS04 and 
mmol) in 1.5 ml of THF, and the resulting mixture was concentrated in vacuo. Flash chromatography with 
stirred for 30 min. Enone 11 (126 mg, 0.30 mmole) in 1.2 20:1 EtOAc/MeOH gave the title product: 27 mg, 72% 
ml ofTHF was added dropwise over 3 min at -too• c. yield; Rp0.21 (20:1 EtOAc/MeOH); 'H NMR 
The resulting mixture was stirred for 2 hr at -too• c., (CDCI3) a 6.91-6.87 (m, 2 H, Ar), 6.70 (t, J =7.5 Hz, 1 
and then another 2 hr at -78• C. Methanol (0.5 ml) was 50 H, Ar), 5.59 (m, 2 H, HC=CH), 5.29 (t, J =6.9 Hz, 1 H, 
added at -78• C. to destroy the excess reducing agent CHOAr), 4.95 (br s, 2 H, OH's), 4.17 (m, 1 H, CHOH), 
and the mixture was allowed to warm to room tempera- 4.03-3.99 (m, 1 H, C=CH-C!!OH), 3.84 (t, J =8.7 Hz, 
ture. After the addition of water (20 ml) and diethyl 1 H, CHAr), 2.75-264 (m, 2H), 2.57-2.48 (m, 1 H), 2.34 
ether (25 ml), stirring was continued for 10 min. The (d, J = 15.3 Hz, 1 H, CH2in cyclopentane), 2.25 (t, 
solution was neutralized with 2 N aqueous HCI, and 55 J = 6.6 Hz, 2 H), 2.16-1.99 (m, 2 H), 1.88-1.76 (m, 1 H), 
then extracted with ether (3 X 30 ml). The organic phase 1.48 (m, 3 H), 1.31 (m, 6 H, CH2's), 0.91 (t, J =6.9 Hz, 3 
was dried over MgS04 and concentrated in vacuo. The H, CH3). This compound has IH NMR spectral data 
crude product was purified by flash chromatography very close to those reported by K. Ohno et al., Tett. 
using 1:2 hexane/EtOAc to give compound 12 (R=Et) Letters, 31, 4489 (1990); 13C NMR (CDCb) 8 178.14, 
(11 mg, 9% yield) and compound 13 (R=Et) (52 mg, 60 158.D2, 136.25, 128.87, 128.38, 127.64, 123.94, 122.75, 
41% yield) as an oil. Starting materialll (14 mg, 11% 119.86, 88.30, 77.00, 73.03, 52.10, 49.87, 41.92, 36.89, 
yield) was also recovered. 32.89, 31.80, 28.79, 25.24, 24.79, 22.72, 14.14; IR (neat) 
Compound 12 (R=Et): Rp0.17 (1:2 hex- 3510 (OH), 2935, 1703 (C=O) em; HRMS m/z calcu-
ane/EtOAc); IH NMR (CDCI3) a 6.92 (d, J =7.5 Hz, 2 lated for C23H320s 388.22497, found 388.22530. 
H, Ar), 6.73 (t, J=7.5 Hz, 1 H, Ar), 5.69-5.67 (m, 2 H, 65 
HC=CH), 5.34 (t, J=7.2 Hz, 1 H, CHOAr), 4.20 (m, I 
H, CHOH), 4.15-4.07 (m, 3 H, OCH2 and 
C=CC!!OH), 3.90 (t, J =9.0 Hz, 1 H, CHAr), 2.79-2.71 
Preparation of compound 15 (R=H) 
To a solution of compound 15 (R=Et) (37 mg, 0.09 
mmol) in 1.2 ml of THF was added 0.6 ml of 3 N aque-
13 
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ous NaOH. After the reaction mixture was stirred for 4 
days at room temperature, it was neutralized with 2 N 
aqueous HCI. The organic phase was decanted with 
EtOAc (3 X 5 ml), then dried over MgS04 and concen- 5 
trated in vacuo. Flash chromatography with 20: I 
EtOAc/MeOH gave compound 15 (R=H): 26 mg, 
74% yield; Rp0.29 (20:1 EtOAc/MeOH); IH NMR 
(CDCl3) a 6.94 (d, 1=7.5 Hz, I H, Ar), 6.9I (d, 1=7.5 
Hz, I H, Ar), 6 73 (t, 1=7.5 Hz, 1 H, Ar), 5.7I (dd, 10 
1 = I5.6 and 5.4 Hz, 1 H, HC=C), 5.64 (dd, 1 = I5.6 and 
7.8 Hz, I H, C=CH), 5.31 (m, 1 H, CHOAr), 4.80 (br s, 
2 H, OR's), 4.I8 (m, IH, C!!OH), 4.10 (dd, 1=Il.7 and 
6.3 Hz, 1 H, C=CC!!OH), 3.88 (t, 1=5.4 Hz, 1 H, 15 CHAr), 2.77 (m, I H), 2.67 (m, I H), 2.55 (m, 1 H), 2.35 
(d, 1 = 15.0 Hz, I H, CH2in cyclopentane), 2.29 (dt, 
1=3.0 and 7.2 Hz, 2 H), 2.I5 (dt, 1=I5.0 and 5.7 Hz, I 
H, CHz in cyclopentane), 2.06 (m, I H), 1.84 (m, I H), 
1.49 (m, 3 H), 1.29 (m, 6 H), 0.89 (t, 1=6.9 Hz, 3 H, 20 
CH3); 13C NMR (CDCb) a I78.17, 157.94, 136.42, 
I28.99, 127.66, 126.78, 124.19, 122.78, 119.98, 88.03, 
76.97, 72.48, 52.3I, 49.96, 42.I6, 37.27, 33.01, 31.83, 
29.02, 25.2I, 24.66, 22.67, I4.I8; IR (neat) 3362 (OH), 25 
2926, 285I, 170I (C=O), I593, 1454 cm-1; HRMS 
calculated for C2H2sOs 388.22497, found 388.22512. 
All patents, patent documents and publications cited 
herein are incorporated by reference herein, as though 
fully set forth. 30 
The invention has been described with reference to 
various specific and preferred embodiments and tech-
niques. However, it should be understood that many 
variations and modifications may be made while re- 35 
maining within the spirit and scope of the invention. 
What is claimed is: 
1. A method for preparing benzoprostacyclins com-
prising reacting a compound of the general formula 
(III): 40 
(III) 
(II) 
wherein R8 and R9 taken together are keto, and Rl, A, 
R2, Band Rs are as defined above. 
2. The method of claim 1, further comprising reduc-
ing the C1s-keto group of compound II with a reducing 
agent to yield a compound of formula II wherein R 8 is 
H and R9 is OH. 
3. A method for preparing benzoprostacyclins com-
prising reacting a compound of the general formula 
(III): 
(III) 
wherein Rl is a pharmaceutically acceptable cation, H 
or (CJ-C12)alkyl; A is -CH2-, -O-CH2-, -CH-
z-CH2- or -CH==CH-; and R2 isH, (C!-Clz)alkyl, 
(C!-Cw)acyl or (C7-C13)aroyl with a compound of a 
general formula (V): 
R 7-CH=C(R 8)(QR3)-CH(f4)-B-R4 (V) 
wherein R5 is (Cz-Cs)alkyl; B is -(CHz)n-Z wherein 
n is 0-4 and Z is -CHzCHz-, -CH==CH- or 
-C=C-; R4 is H, F, CH3 or CHzCH3; and R7 is 
((C1-C4)alkyi)3Sn or (phenyl)3Sn, R8 is (C1-C12)-alkyl 
45 or H; and R3 is H, (Ct-Ctz)alkyl, (CJ-Cw)acyl or 
(C7-C13)aroyl; wherein the reaction is carried out in the 
presence of a catalytic amount of a free radical initiator 
to yield a compound of the formula (II): 
50 
wherein R 1 is a pharmaceutically-acceptable cation, H 
or (CJ-C12)alkyl; A is -CHz-, -0-CHz-, -CH-
z-CHz- or -CH==CH-; and R2 isH, (CJ-CI2)alkyl, 55 
(CI-Cw)acyl or (C7-C13)aroyl with a compound of a 
general formula (IV): 
R 7-CH=CH-C(O)-CH(~)-B-Rs (IV) 
60 
wherein R5 is (Cz-Cs)a1kyl; B is -(CHz),-Z wherein 
n is 0-4 and Z is -CHzCHz-, -CH==CH- or 
-CsC-; R4 is H, F, CH3 or CHzCH3; and R7 is 
((C1-C4)alkyi)3Sn or (phenyi)3Sn wherein the reaction 65 
is carried out in the presence of a catalytic amount of a 
free radical initiator to yield a compound of the formula 
(II): 
(II) 
wherein R9is OR3, and Rl, A, R2, R3, R4, B, R5and Rs 
are as defined above. 
4. The method of claims 1 or 3 wherein R7 is (n-
butyl)3Sn. 
5. The method of claim 3 wherein R 3 is H in com-
pounds II and V. 
6. The method of claims 2 or 3 wherein compound II 
comprises (S)C1s-OH. 
15 
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7. The method of claim 6wherein the CII-QR2bond 
is in the alpha-configuration. 
8. The method of claim 1 wherein, in compound III, 
Rl is (CI-Cl2)alkyl and R2 is H. 
9. The method of claims 2 or 3 further comprising 5 
saponifying the C02R 1 moiety of compound II and 
neutralizing the reaction mixture to yield C02H. 
10. The method of claim 9 further comprising form-
ing a pharmaceutically acceptable alkali metal salt, am- IO 
monium, or amine salt of the moiety C02H. 
11. The method of claims 1 or 3 wherein the free 
radical initiator is AIBN. 
15 
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12. The method of claim 1 wherein the reaction is 
carried out in solution in an organic solvent. 
13. The method of claim 2 wherein the reaction is 
carried out at about so· -150' c. 
14. The method of claim 13 wherein the reaction is 
carried out for about 5-48 hours. 
15. The method of claim 1 wherein the mole ratio of 
III:IV is about 1:1.25-20. 
16. The method of claim 1 wherein A is -CH2- or 
-CH2-CH2- and B is CH2-CH2-CH2. 
17. The method of claim 16 wherein R 4 is H and R5 is 
CH3. 
• • • • • 
